Skip to content

Cancer - What is R-CHOP

Reading time 7 minutes
Convert to PDF

R-CHOP is used as chemotherapy for cancer.

The following post provides a comprehensive overview of the R-CHOP chemotherapy regimen, which is one of the most important standard therapies for aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL).
In addition to explaining the individual active ingredients Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone, their mechanisms of action, pharmacology, typical side effects, and relevant risks and monitoring strategies are presented in detail.

Particular emphasis is placed on the temporal progression of therapy over multiple cycles. The schematic cycle diagrams illustrate typical hematological changes such as neutropenia, thrombocytopenia, and anemia, explain cumulative toxicities—particularly neurotoxicity and cardiotoxicity—and classify these based on published study data.
In addition, supportive measures such as G-CSF prophylaxis, adjunctive anti-infective therapies, and evidence-based supplementation are described, and potentially problematic natural substances and drug interactions are listed.

The content is intended to provide a scientifically grounded overview and illustration of typical R-CHOP treatment courses; however, it is not a substitute for an individual medical evaluation or treatment decision.

R-CHOP

R-CHOP is a CHOP treatment regimen extended to include the active ingredient Rrituximab.

Active ingredients

Rituximab

is a monoclonal antibody, a chimeric IgG1κ (composed of genetically distinct cells), that specifically binds to the CD20 antigen binds to the surface of B lymphocytes and is used, for example, in non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and certain vasculitides, as well as pemphigus vulgaris, and is administered as a single dose on the first day of each cycle at 375 mg/m² intravenously (i.v.) or, starting from the second cycle, at 1,400 mg subcutaneously (s.c.).
It is metabolized (broken down) by the liver and immune system cells and has a half-life (50% plasma concentration) of approximately 29 days.
Rituximab marks CD20-expressing B lymphocytes as target cells for the immune system, thereby inducing their apoptosis (cell death).
According to the current state of research, rituximab is the antibody with the fewest adverse side effects in DLBCL.

CHOP stands for the other four drugs:

Ccyclophosphamide

a so-called. Prodrug, i.e., it only exhibits its cytotoxic and immunosuppressive properties after being activated in the liver. It inhibits DNA replication (the duplication of DNA molecules), transcription (the transfer of genetic information from a DNA strand to RNA), and cell division (the formation of new cells through the constriction of the parent cell, e.g., like an „8,“ both parts of which contain identical information and components), ultimately triggering apoptosis (cell death) of the tumor cells.
It is administered orally as a tablet or capsule, or as a powder dissolved in infusion solution, intravenously. The half-life is between 3 and 12 hours. The liver and kidneys metabolize and excrete the active ingredient.

HHydroxydaunorubicin

also known as doxorubicin – blocks transcription and inhibits the enzyme topoisomerase II. It is metabolized by the liver and bile. Liposomal formulations reduce cardiotoxicity and exposure to healthy tissues!
It is embryo- and fetotoxic and impairs reproductive capacity, which is why contraception is mandatory.
It causes a temporary increase in liver enzyme levels (transaminases and bilirubin). When bilirubin levels are elevated, the elimination of the active ingredient is significantly delayed—as is also the case following gallbladder removal—which intensifies unwanted side effects.
The enzyme active in heart muscle cells Topoisomerase IIβ is also inhibited and causes cumulative, total-dose-dependent(!) cardiotoxicity as the most severe long-term side effect, which can progress to life-threatening heart failure:
– increased clinical observation is indicated from a dose of 250–300 mg/m²
– At 500 mg/m² or higher, the risk is 16%
– 700 mg/m² and above 48%
ECG monitoring and monitoring of the biomarkers BNP, NT-proBNP, and troponin are mandatory: In cases of reduced ventricular function, the prognosis can be improved by administering ACE inhibitors and beta-blockers.

Oncovin (vincristine)

inhibits the formation of the mitotic spindle apparatus and thus the cell division of rapidly dividing cells. However, the function of axonal microtubules, the intracellular transport in neurons (nerve cells), is also impaired, leading to peripheral neuropathies and neurological side effects.
It is eliminated via the liver, bile, and feces. Impaired liver/biliary function results in a longer half-life and increased side effects.
Oncovin is only available as a solution for infusion and must be administered exclusively intravenously. Intrathecal administration is usually fatal, and extravasal administration can cause tissue damage!
Dosage (according to the manufacturer’s instructions!) e.g., for adults and children: 1.4 mg/m² once weekly (max. 2 mg per dose); for infants: initial dose of 0.05 mg/kg. If direct serum bilirubin is elevated above 3 mg/dL or there is liver dysfunction, a 50% reduction in the initial dose is recommended.
The half-life is initially about 5 minutes, intermediate at approximately 2.3 hours, and terminal (50% of the % plasma concentration) at 85 hours.

Prednison

is a prodrug of prednisolone, which is activated in the liver and has immunosuppressive and antiphlogistic (anti-inflammatory) effects.
It can be administered orally and intravenously. Its half-life in plasma is 2 to 4 hours, and its biological efficacy ranges between 12 and 36 hours.
It is 4 times more potent than the body's own cortisol (hydrocortisone), its so-called Cushing's dose (the dose at which Cushing's syndrome - hypercortisolism can occur) is 7.5 mg/d. The threshold is in patients with, for example.
– rheumatoid arthritis (chronic inflammatory systemic disease affecting the joint lining)
– Polymyalgia rheumatica (PMR - autoimmune disease)
– relapsing polychondritis (a disease that destroys cartilage)
– Multiple Sclerosis (MS – chronic inflammatory demyelinating disease of the CNS)
– Glomerulonephritis (inflammation of the filtering system—the glomeruli—in the renal cortex)
– Crohn's disease (IBD – inflammatory bowel disease, specifically affecting the ileum and colon)
– Ulcerative colitis (chronic inflammatory bowel disease)

R-CHOP - Cycles

The following overviews reflect the typical course of the disease as observed in clinical studies.

Instructions

Hovering the mouse over the timeline representing an active ingredient's duration of action displays a pop-up with information on the active ingredient, dosage, blood levels, supplementation, side effects, or precautions.

Mouse-over on hematologic trend curves displays nadir data, trends, effects, prophylaxis, monitoring, and intervention notes.

Active ingredients, hematologic toxicity, and iron metabolism

1. Cycle

    R-CHOP Cycle 1 — Active Ingredients, Hematological Toxicity & Iron Metabolism

    Schematic timeline (21 days, days 1–21 of the entire treatment).

    First exhibition with myelosuppressive agents. Pre-cycle ANC is often elevated due to lymphoma-related inflammation. Median ANC nadir 0.4 G/L [1]. Thrombocytopenia is usually mild (grade 3–4 in only ~61% of patients). Hemoglobin decline in cycle 1 is minimal.
    Evidence base for the anchor points (hematological parameters):
    [1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 (PubMed: PMID 11807147): Median ANC nadir 0.4 G/L; Grade 3–4 anemia 14%; Grade 3–4 thrombocytopenia 6%
    [2] Pettengell & Aapro et al., Drugs 2009;29(8):491 & Aapro et al., EORTC G-CSF, Eur J Cancer 2011;47:8–32 (PMID 21095116): FN risk R-CHOP ~20%
    [3] GELA 2002 [1]
    [4] Clausen & Ulrichsen, Leuk Lymphoma 2019: Grade 4 neutropenia in 45% after cycle 1
    Iron parameters (ferritin, CRP, Fe, TSAT): purely schematic — no published serial R-CHOP follow-up data available. Curve shapes interpolated between anchor points (no daily measurements reported in the literature).
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    2. Cycle

    R-CHOP Cycle 2 — Active Ingredients, Hematologic Toxicity & Iron Metabolism

    Schematic timeline (21 days; days 22–42 of the total treatment).

    Pre-cycle readings are falling mild (cumulative effect on bone marrow). Minimum depths remain stable — No significant difference from Cycle 1 [1,3]. LDH levels should have normalized (response to treatment). The drop in Hb remains minimal.
    Evidence base for the anchor points (hematological parameters):
    [1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 (PubMed: PMID 11807147): Median ANC nadir 0.4 G/L; Grade 3–4 anemia 14%; Grade 3–4 thrombocytopenia 6%
    [2] Pettengell & Aapro et al., Drugs 2009;29(8):491 & Aapro et al., EORTC G-CSF, Eur J Cancer 2011;47:8–32 (PMID 21095116): FN risk R-CHOP ~20%
    [3] GELA 2002 [1]
    [4] Clausen & Ulrichsen, Leuk Lymphoma 2019: Grade 4 neutropenia in 45% after cycle 1
    Iron parameters (ferritin, CRP, Fe, TSAT): purely schematic — no published serial R-CHOP follow-up data available. Curve shapes interpolated between anchor points (no daily measurements reported in the literature).
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    3rd Cycle

    R-CHOP Cycle 3 – Active Ingredients, Hematological Toxicity & Iron Metabolism

    Schematic timeline (21 days, days 43–63 of the overall treatment).

    ⚠ Cumulative effect on previous values: Pre-cycle ANC decreases over the course of the cycles (9.67 → 4.14 g/L by cycle 6). However, nadir depths remain stable — No significant difference between cycles 1 and 6 in G-CSF prophylaxis.
    Evidence base for the anchor points (hematological parameters):
    [1] Coiffier et al., GELA, NEJM 2002: Median ANC nadir 0.4 G/L after cycle 1; grade 3–4 anemia in 141 patients; grade 3–4 thrombocytopenia in 61 patients
    [2] Saidi et al., EHA 2021: FN rate 2.71 TP3T with G-CSF vs. 7.41 TP3T without
    [3] GELA 2002 [1]
    [4] Clausen & Ulrichsen et al., Leuk Lymphoma 2019: Grade 4 neutropenia in 45% after cycle 1
    Iron parameters (ferritin, CRP, Fe, TSAT): purely schematic — no published serial R-CHOP follow-up data available. Curve shapes between anchor points are interpolated (no daily measurements are available in the literature).
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    4th cycle

    R-CHOP Cycle 4 — Active Ingredients, Hematological Toxicity & Iron Metabolism

    Schematic timeline (21 days, days 64–84 of the overall treatment).

    Pre-cycle readings continue to decline [3]. Lowest depths remain stable (No significant difference between cycles 1–6 [1,3]). Cumulative doxorubicin dose of 200 mg/m². Normalization of LDH = sustained response.
    Evidence base for the anchor points:
    [1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 (PubMed: PMID 11807147): Median ANC nadir 0.4 G/L; Grade 3–4 anemia 14%; Grade 3–4 thrombocytopenia 6%
    [2] Saidi et al., EHA 2021: FN rate 2.71% with G-CSF
    [3] Coiffier et al. GELA NEJM 2002 [1] (per-cycle ANC data): stable nadir levels across cycles 1–8; pre-cycle ANC decreases gradually. Note: previously cited „GELA 2002 [1]”
    [4] Clausen MR & Ulrichsen SP et al., Leuk Lymphoma 2019;60(8) (doi: 10.1080/10428194.2018.1554863): Grade 4 neutropenia in the 45% trial (432 out of 965 patients) after cycle 1 of R-CHOP.
    Treatment parameters: purely schematic — no published serial R-CHOP follow-up data.
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    5. Cycle

    R-CHOP Cycle 5 — Active Ingredients, Hematologic Toxicity & Iron Metabolism

    Schematic timeline (21 days, days 85–105 of the overall treatment).

    Cumulative effect on bone marrow reserve. ANC's Nadir Remains Stable at ~0.4 g/L [1,3]. Cumulative doxorubicin dose of 250 mg/m². Intensify monitoring for vincristine-induced neuropathy.
    Evidence base for the anchor points:
    [1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 (PubMed: PMID 11807147): Median ANC nadir 0.4 G/L; Grade 3–4 anemia 14%; Grade 3–4 thrombocytopenia 6%
    [2] Saidi et al., EHA 2021: FN rate 2.71% with G-CSF
    [3] Coiffier et al. GELA NEJM 2002 [1] (per-cycle ANC data): stable nadir levels across cycles 1–8; pre-cycle ANC decreases gradually. Note: previously cited „GELA 2002 [1]”
    [4] Clausen MR & Ulrichsen SP et al., Leuk Lymphoma 2019;60(8) (doi: 10.1080/10428194.2018.1554863): Grade 4 neutropenia in the 45% trial (432 out of 965 patients) after cycle 1 of R-CHOP.
    Treatment parameters: purely schematic — no published serial R-CHOP follow-up data.
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    6th Cycle

    R-CHOP Cycle 6 — Active Ingredients, Hematologic Toxicity & Iron Metabolism

    Schematic timeline (21 days, days 106–126 of the overall treatment). — Last standard cycle of R-CHOP-21 × 6.

    Last standard cycle of the R-CHOP 21 × 6 regimen. Cumulative doxorubicin dose of 300 mg/m². Final evaluation: PET-CT after cycle 6. LVEF assessment. Documentation of neuropathy.
    Evidence base for the anchor points:
    [1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 (PubMed: PMID 11807147): Median ANC nadir 0.4 G/L; Grade 3–4 anemia 14%; Grade 3–4 thrombocytopenia 6%
    [2] Saidi et al., EHA 2021: FN rate 2.71% with G-CSF
    [3] Coiffier et al. GELA NEJM 2002 [1] (per-cycle ANC data): stable nadir levels across cycles 1–8; pre-cycle ANC decreases gradually. Note: previously cited „GELA 2002 [1]”
    [4] Clausen MR & Ulrichsen SP et al., Leuk Lymphoma 2019;60(8) (doi: 10.1080/10428194.2018.1554863): Grade 4 neutropenia in the 45% trial (432 out of 965 patients) after cycle 1 of R-CHOP.
    Treatment parameters: purely schematic — no published serial R-CHOP follow-up data.
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    7. Cycle

    R-CHOP Cycle 7 — Active Ingredients, Hematological Toxicity & Iron Metabolism

    Schematic timeline (21 days, days 127–147 of total therapy). — Extended protocol (not the standard R-CHOP-21 × 6 regimen).

    Outside the standard framework (R-CHOP-21 × 6). Check the indication (e.g., R-CHOP-14 protocol, high-risk patient). Cumulative doxorubicin dose: 350 mg/m². LVEF monitoring is mandatory.
    Evidence base for the anchor points:
    [1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 (PubMed: PMID 11807147): Median ANC nadir 0.4 G/L; Grade 3–4 anemia 14%; Grade 3–4 thrombocytopenia 6%
    [2] Saidi et al., EHA 2021: FN rate 2.71% with G-CSF
    [3] Coiffier et al. GELA NEJM 2002 [1] (per-cycle ANC data): stable nadir levels across cycles 1–8; pre-cycle ANC decreases gradually. Note: previously cited „GELA 2002 [1]”
    [4] Clausen MR & Ulrichsen SP et al., Leuk Lymphoma 2019;60(8) (doi: 10.1080/10428194.2018.1554863): Grade 4 neutropenia in the 45% trial (432 out of 965 patients) after cycle 1 of R-CHOP.
    Treatment parameters: purely schematic — no published serial R-CHOP follow-up data.
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    8th cycle

    R-CHOP Cycle 8 — Active Ingredients, Hematological Toxicity & Iron Metabolism

    Schematic timeline (21 days, days 148–168 of the overall treatment). — Extended protocol (not the standard R-CHOP-21 × 6 regimen).

    Outside the standard framework. Cumulative doxorubicin dose of 400 mg/m² — an echocardiogram to assess LVEF is mandatory before cycle 8. Highest cumulative risk of neuropathy and cardiotoxicity.
    Evidence base for the anchor points:
    [1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 (PubMed: PMID 11807147): Median ANC nadir 0.4 G/L; Grade 3–4 anemia 14%; Grade 3–4 thrombocytopenia 6%
    [2] Saidi et al., EHA 2021: FN rate 2.71% with G-CSF
    [3] Coiffier et al. GELA NEJM 2002 [1] (per-cycle ANC data): stable nadir levels across cycles 1–8; pre-cycle ANC decreases gradually. Note: previously cited „GELA 2002 [1]”
    [4] Clausen MR & Ulrichsen SP et al., Leuk Lymphoma 2019;60(8) (doi: 10.1080/10428194.2018.1554863): Grade 4 neutropenia in the 45% trial (432 out of 965 patients) after cycle 1 of R-CHOP.
    Treatment parameters: purely schematic — no published serial R-CHOP follow-up data.
    Active Ingredients — Application & Duration of Action
    Hematological trend charts
    Iron Metabolism & Inflammation Markers schematic

    R-CHOP cycle-dependent supplementation

    The following recommendations are evidence-based and therefore do not include naturopathic remedies.

    By clicking on the tabs at the top, you can select the current cycle and view the relevant data.
    Clicking on a row will display information on dosage, timing, mechanisms of action, and references.

    Sections highlighted in red contain information on contraindications, including relevant explanations.

    Evidence-based and cycle-dependent. Clinical decisions are always made on a case-by-case basis. This is not a medical recommendation.

    Sources of evidence:
    [A] EORTC 2011/2019 · ASCO 2015 · NCCN 2023 · ESMO/IDSA · EULAR/DGE
    [B] Steinmetz et al. 2013 · Auerbach et al. 2004 · ESMO Anemia Guidelines
    [C] Longo et al. 2014 · Morisco et al. 1993 · Greenlee et al. 2014 · Argyriou et al. 2006
    Contraindications: D’Andrea 2005 · Sparreboom et al. 2004

    Level A = Consistent with guidelines · B = Moderate evidence · C = Limited evidence · X = Avoid

    Leave a Reply

    Your email address will not be published. Required fields are marked *